# Aqemia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aqemia

- Industry: Pharmaceuticals
- Headquarters: Paris, France
- Website: www.aqemia.com
- Total disclosed funding: $62M
- Latest round: Series A (Jan 30, 2024)
- Investors on record: 4

## About

Based in Paris, France, and founded in 2019 by co-founders Maximilien Levesque (CEO) and Emmanuelle Martiano, Aqemia operates as a pharmatech company that develops an AI-based drug discovery platform that analyzes drug candidates and therapeutic targets for critical diseases. In January 2024, Aqemia raised EUR 30 million in Series A funding led by Wendel, with participation from Bpifrance Investissement, Eurazeo, and Elaia Partners. The round was part of a larger EUR 60 million series A funding. In December 2024, Aqemia raised EUR 36 million in venture funding led by Cathay Capital, with participation from Bpifrance Investissement, Elaia Partners, Eurazeo, and Wendel. The company provides a wide range of drug discovery services, such as a proprietary therapeutic pipeline, genAI powered by physics, and quantum-inspired physics technology. Additionally, the firm also provides AI-enabled drug discovery solutions.

## Funding rounds

- Series A, Jan 30, 2024, $32M — Elaia Partners, Eurazeo, Wendel, Bpifrance Investissement
- Series A, Oct 7, 2022, $29M — Elaia Partners, Eurazeo, Bpifrance Investissement

## Investors

- Elaia Partners (https://capitalatlas.ai/funds/elaia-partners) — Series A
- Eurazeo (https://capitalatlas.ai/funds/eurazeo) — Series A
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A
- Wendel (https://capitalatlas.ai/funds/wendel) — Series A